Value-Based Medtech Rides The Money-Go-Round Into 2016
Executive Summary
The wider medtech industry saw only 2% growth in 2015, and medtechs in established markets face continued low growth for the next three to five years. The medtech M&A bonanza continued into 2015 and there is no end in sight in 2016 as manufacturers seek to augment and fine-tune portfolios to meet the new demands of payers and providers; longer term, there are signs of a change in the top global medtech rankings.
You may also be interested in...
St. Jude's CardioMEMS Showing Results In HF
Results from the CHAMPION study give St. Jude hope that its CardioMEMS system will stem the tide of heart failure.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.